AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02626182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: active sildenafil
Study NCT02626182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill that looks like sildenafil tablets
Study NCT01410695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib 3 mg
Study NCT03400540 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: verbal instruction
Description: Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
Study NCT01410695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib 6.0 mg
Study NCT01410695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00724282 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eszopiclone
Description: Eszopiclone 3 mg by mouth daily at bedtime for 9 days
Study NCT01410695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (methotrexate)
Study NCT00724282 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo by mouth daily at bedtime for 9 days
Study NCT01432366 — intervention group
Intervention type: OTHER
Intervention: SC anti-TNF
Description: Subcutaneous (SC) anti-TNF
Study NCT03207412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: human amniotic epithelial cells
Study NCT01410695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (masitinib)
Study NCT02926183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
Description: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
Study NCT00956683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Infraclavicular Nerve Block
Description: Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
Study NCT03207412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive implantation
Description: Minimally invasive implantation with ultrasound guidance
Study NCT03278665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-202 in combination with Pembrolizumab
Description: 4SC-202 in combination with Pembrolizumab
Study NCT00956683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual-Endpoint nerve stimulation
Description: Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
Study NCT04087382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
Study NCT04087382 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non intervention group
Description: medical treatment (Asprin, statin, nootropic drug)
Study NCT02437890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Study NCT00304278 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RAD)
Description: 5 days per week X 7 weeks
Study NCT00518310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00518310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZAPRED
Description: The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
Study NCT04489446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.
Study NCT04489446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.
Study NCT04431323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESPRIMO
Description: Participants will receive the intervention during Phase 2.~The intervention is based on the cognitive behavioral, the third-wave (mindfulness and acceptance and commitment therapy), and the positive psychology approach.~The frequency of the intervention and the specific content and aims of the psychological and physical intervention will be based on the results of the surveys and the focus group discussion (Pre-phase and Phase 1). In order to maximize the benefit of the integrated intervention, all the three components of the interventions (i.e., psychological, motor exercise and social components) will be administered in the same time period.~A preliminary theoretical framework of the intervention will be created prior to the survey phase according to the literature in the field. Specific aspects of this preliminary framework will be discussed during the co-creation phase and adapted after the analysis of the qualitative results.
Study NCT02437890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02437890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02148783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with \[11C\]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
Study NCT02148783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03165643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OGTT
Description: 75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
Study NCT02614937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg IVT ranibizumab
Study NCT03518047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: rizankizumab subcutaneous (SC) infusion
Study NCT02614937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate Ophthalmic Solution, 0.2%
Description: Squalamine Lactate Ophthalmic Solution BID
Study NCT03518047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for rizankizumab
Description: placebo for rizankizumab subcutaneous (SC) infusion
Study NCT02515500 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gradual Cessation
Study NCT02515500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual Cessation w/ Quitbit
Study NCT01347099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
Study NCT03666039 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trainings app
Description: Sensorimotor trainings app for at home Training (tablet-based)
Study NCT03666039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trainings app
Description: Sensorimotor trainings app for at home Training (tablet-based)
Study NCT04073043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching
Description: Access to Telephone Coaching for a period of 12 weeks
Study NCT02924103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contamination free bacterial swab
Description: A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule.
Study NCT01343511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood mononuclear cells
Description: Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
Study NCT01343511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells
Description: Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
Study NCT02932618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (Recombinant)
Description: Lyophilized powder and solvent to prepare solution for injection.
Study NCT02932618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant)
Description: Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
Study NCT01418261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation (Symplicity Catheter System)
Study NCT01418261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Renal angiogram
Study NCT01418261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal angiogram
Study NCT01068873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus maraviroc
Description: Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
Study NCT01297192 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: solifenacin succinate
Description: Oral
Study NCT01297192 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: mirabegron
Description: Oral
Study NCT01493531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 200 mg QD
Study NCT01493531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 400 mg QD
Study NCT01493531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo QD
Study NCT01493531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Tablets
Study NCT01493531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Tablets
Study NCT04265755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI).
Study NCT02624804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator Therapy
Description: Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes
Study NCT01917526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen mask
Study NCT01917526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen cannula
Study NCT00446316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antacids (Mg-Al-based)
Description: the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
Study NCT00446316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatimib Mesylate (Gleevec®)
Description: Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
Study NCT04459611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
Study NCT04459611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study NCT04459611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 1.
Study NCT04459611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: 260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet
Study NCT00562159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 697243
Description: SCH 697243 (2800 Bioequivalent Allergen Units \[BAU\] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine 10 mg Rescue Treatment
Description: Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg Rescue Treatment
Description: Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olopatadine 0.1% Rescue Treatment
Description: Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1% Rescue Treatment
Description: Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone 50 mcg Rescue Treatment
Description: Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone 50 mcg Rescue Treatment
Description: Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 5 mg Rescue Treatment
Description: Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg Rescue Treatment
Description: Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol sulfate 108 mcg
Description: Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate 108 mcg
Description: Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate 44 mcg
Description: Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 44 mcg
Description: Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone 5 mg
Description: Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
Study NCT00562159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg
Description: Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
Study NCT00254982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
Study NCT03956303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine %0.5
Description: Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
Study NCT03956303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine Heavy 40
Description: Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
Study NCT03956303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine Heavy 60
Description: Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
Study NCT03956303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine Heavy 80
Description: Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
Study NCT00317239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325 mg/TID x 8 weeks
Study NCT01347099 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Support therapy on Internet
Description: Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
Study NCT04792541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HY containing gel; GUM® Afta Clear Gel, Sunstar
Study NCT03091894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
Study NCT03091894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
Study NCT00317239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
Study NCT01799174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UVA-1 Phototherapy
Study NCT01799174 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo